Accelerator Mass Spectrometer segmentation by application reveals five primary sub‑segments that collectively drive market revenue. Radiocarbon dating accounts for roughly 30 % of sales, reflecting sustained demand from archaeology, geology and climate‑reconstruction projects that require ultra‑low‑level ^14C measurements. Biomedical research represents about 25 %, as pharmaceutical and clinical laboratories adopt AMS for tracer studies, drug metabolism and pharmacokinetic profiling, which command higher unit prices. Environmental monitoring contributes 20 %, encompassing isotopic analysis of greenhouse gases, water quality and soil contaminants, where regulatory mandates stimulate recurring purchases. Nuclear forensics holds 15 % of the market, driven by security agencies that rely on AMS to identify illicit nuclear material signatures, a segment characterized by premium service contracts. Finally, materials science captures the remaining 10 %, supporting research on thin‑film deposition, semiconductor doping and advanced alloys. These percentages are reflected in the accompanying pie‑chart, illustrating how each application sub‑segment underpins the overall Accelerator Mass Spectrometer market size. The relative weighting also guides OEMs in prioritizing feature development and after‑sales support.